These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 26316040)

  • 21. Pharmacokinetics of hydroxychloroquine in paediatric lupus: data from a novel, direct-to-family clinical trial.
    Balevic SJ; Randell R; Weiner D; Beard C; Schanberg LE; Hornik CP; Cohen-Wolkowiez M; Gonzalez D;
    Lupus Sci Med; 2022 Nov; 9(1):. PubMed ID: 36328395
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam.
    Veiga MI; Asimus S; Ferreira PE; Martins JP; Cavaco I; Ribeiro V; Hai TN; Petzold MG; Björkman A; Ashton M; Gil JP
    Eur J Clin Pharmacol; 2009 Apr; 65(4):355-63. PubMed ID: 18979093
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Whole blood hydroxychloroquine: Does genetic polymorphism of cytochrome P450 enzymes have a role?
    Jatta N; Stanslas J; Yong ACH; Ho WC; Wan Ahmad Kammal WSL; Chua EW; How KN
    Clin Exp Med; 2023 Dec; 23(8):4141-4152. PubMed ID: 37480404
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of Cytochrome P450 2D6 Polymorphisms on the Efficacy of Oral Propranolol in Treating Infantile Hemangioma.
    Wang L; Zheng K; Li X; Wang Y; Xu Q
    Biomed Res Int; 2020; 2020():8732871. PubMed ID: 32219146
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hydroxychloroquine Levels throughout Pregnancies Complicated by Rheumatic Disease: Implications for Maternal and Neonatal Outcomes.
    Balevic SJ; Cohen-Wolkowiez M; Eudy AM; Green TP; Schanberg LE; Clowse MEB
    J Rheumatol; 2019 Jan; 46(1):57-63. PubMed ID: 30275257
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus.
    Costedoat-Chalumeau N; Amoura Z; Hulot JS; Aymard G; Leroux G; Marra D; Lechat P; Piette JC
    Ann Rheum Dis; 2007 Jun; 66(6):821-4. PubMed ID: 17324970
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of Hydroxychloroquine as a Perpetrator on Cytochrome P450 (CYP) 3A and CYP2D6 Activity with Microdosed Probe Drugs in Healthy Volunteers.
    Stoll F; Blank A; Mikus G; Czock D; Weiss J; Meyer-Tönnies MJ; Gümüs KS; Tzvetkov M; Burhenne J; Haefeli WE
    Eur J Drug Metab Pharmacokinet; 2024 Jan; 49(1):101-109. PubMed ID: 38114885
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of genetic polymorphisms of CYP2D6, CYP3A5, and ABCB1 on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia.
    Suzuki T; Mihara K; Nakamura A; Kagawa S; Nagai G; Nemoto K; Kondo T
    Ther Drug Monit; 2014 Oct; 36(5):651-5. PubMed ID: 24682161
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study).
    Costedoat-Chalumeau N; Galicier L; Aumaître O; Francès C; Le Guern V; Lioté F; Smail A; Limal N; Perard L; Desmurs-Clavel H; Boutin du LT; Asli B; Kahn JE; Pourrat J; Sailler L; Ackermann F; Papo T; Sacré K; Fain O; Stirnemann J; Cacoub P; Jallouli M; Leroux G; Cohen-Bittan J; Tanguy ML; Hulot JS; Lechat P; Musset L; Amoura Z; Piette JC;
    Ann Rheum Dis; 2013 Nov; 72(11):1786-92. PubMed ID: 23144449
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers.
    Belmonte C; Ochoa D; Román M; Saiz-Rodríguez M; Wojnicz A; Gómez-Sánchez CI; Martín-Vílchez S; Abad-Santos F
    Basic Clin Pharmacol Toxicol; 2018 Jun; 122(6):596-605. PubMed ID: 29325225
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical impact of hydroxychloroquine dose adjustment according to the American Academy of Ophthalmology guidelines in systemic lupus erythematosus.
    Vázquez-Otero I; Medina-Cintrón N; Arroyo-Ávila M; González-Sepúlveda L; Vilá LM
    Lupus Sci Med; 2020 May; 7(1):. PubMed ID: 32434863
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quality of life in systemic lupus erythematosus: description in a cohort of French patients and association with blood hydroxychloroquine levels.
    Jolly M; Galicier L; Aumaître O; Francès C; Le Guern V; Lioté F; Smail A; Limal N; Perard L; Desmurs-Clavel H; Boutin DL; Asli B; Kahn JE; Pourrat J; Sailler L; Ackermann F; Papo T; Sacré K; Fain O; Stirnemann J; Cacoub P; Jallouli M; Leroux G; Cohen-Bittan J; Hulot JS; Arora S; Amoura Z; Piette JC; Costedoat-Chalumeau N;
    Lupus; 2016 Jun; 25(7):735-40. PubMed ID: 26876692
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A linked physiologically based pharmacokinetic model for hydroxychloroquine and metabolite desethylhydroxychloroquine in SARS-CoV-2(-)/(+) populations.
    Steinbronn C; Chhonker YS; Stewart J; Leingang H; Heller KB; Krows ML; Paasche-Orlow M; Bershteyn A; Stankiewicz Karita HC; Agrawal V; Laufer M; Landovitz R; Wener M; Murry DJ; Johnston C; Barnabas RV; Arnold SLM
    Clin Transl Sci; 2023 Jul; 16(7):1243-1257. PubMed ID: 37118968
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and Safety of Hydroxychloroquine Therapy for Systemic Lupus Erythematosus Patients Depend on Administration Dose.
    Wakiya R; Kameda T; Nakashima S; Shimada H; Fahmy Mansour MM; Kato M; Miyagi T; Kadowaki N; Dobashi H
    Intern Med; 2020 Sep; 59(17):2105-2112. PubMed ID: 32522920
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hydroxychloroquine: a multifaceted treatment in lupus.
    Costedoat-Chalumeau N; Dunogué B; Morel N; Le Guern V; Guettrot-Imbert G
    Presse Med; 2014 Jun; 43(6 Pt 2):e167-80. PubMed ID: 24855048
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Supplemental hydroxychloroquine therapy regulates adipokines in patients with systemic lupus erythematosus with stable disease.
    Wakiya R; Ueeda K; Shimada H; Nakashima S; Kameda T; Miyatake N; Kato M; Miyagi T; Sugihara K; Mizusaki M; Mino R; Kadowaki N; Dobashi H
    Clin Rheumatol; 2022 Nov; 41(11):3345-3353. PubMed ID: 35849246
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Individual differences in in vitro and in vivo metabolic clearances of antipsychotic risperidone from Japanese subjects genotyped for cytochrome P450 2D6 and 3A5.
    Okubo M; Morita S; Murayama N; Akimoto Y; Goto A; Yamazaki H
    Hum Psychopharmacol; 2016 Mar; 31(2):93-102. PubMed ID: 26856541
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Health status and concomitant prescription of immunosuppressants are risk factors for hydroxychloroquine non-adherence in systemic lupus patients with prolonged inactive disease.
    Iudici M; Pantano I; Fasano S; Pierro L; Charlier B; Pingeon M; Dal Piaz F; Filippelli A; Izzo V
    Lupus; 2018 Feb; 27(2):265-272. PubMed ID: 28659047
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of cytochrome P450 2D6 and 3A5 genotypes and possible coadministered medicines on the metabolic clearance of antidepressant mirtazapine in Japanese patients.
    Okubo M; Murayama N; Miura J; Chiba Y; Yamazaki H
    Biochem Pharmacol; 2015 Jan; 93(1):104-9. PubMed ID: 25475885
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Longterm Hydroxychloroquine Therapy and Low-dose Aspirin May Have an Additive Effectiveness in the Primary Prevention of Cardiovascular Events in Patients with Systemic Lupus Erythematosus.
    Fasano S; Pierro L; Pantano I; Iudici M; Valentini G
    J Rheumatol; 2017 Jul; 44(7):1032-1038. PubMed ID: 28507183
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.